country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-N10452

Copy Link Print Information

Methyl maslinate

Name: Methyl maslinate
Brand: MedChemExpress
SKU: HY-N10452
Price: 140.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Customer Review

Based on 1 Customer Validation

Methyl maslinate is a β-adrenergic antagonist. Methyl maslinate is a potent cardiotonic and antidysrhythmic agent. Methyl maslinate has the potential for hypertension research.

For research use only. We do not sell to patients.

Purity : 98.0%
CAS No.: 22425-82-7
Formula: C₃₁H₅₀O₄
Molecular Weight:486.73

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Methyl maslinate Chemical Structure

CAS No.: 22425-82-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vivo
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Methyl maslinate is a β-adrenergic antagonist. Methyl maslinate is a potent cardiotonic and antidysrhythmic agent. Methyl maslinate has the potential for hypertension research^[1].

IC₅₀ & Target

β adrenergic receptor

All Adrenergic Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	IC₅₀	15.6 μM Compound: 11	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
518A2	IC₅₀	15.6 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24161703]
8505C	IC₅₀	14.7 μM Compound: 11	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
8505C	IC₅₀	14.7 μM Compound: 2	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24161703]
A2780	IC₅₀	17.3 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24161703]
A2780	IC₅₀	17.8 μM Compound: 11	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	17.8 μM Compound: 11	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	17.8 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24161703]
HT-29	IC₅₀	12.8 μM Compound: 11	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	IC₅₀	12.8 μM Compound: 2	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24161703]
MCF7	IC₅₀	16.3 μM Compound: 11	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	IC₅₀	16.3 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24161703]
NIH3T3	IC₅₀	21.4 μM Compound: 11	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
NIH3T3	IC₅₀	21.4 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24161703]

In Vivo

Methyl maslinate (MM) (20-60 mg/kg; i.p.) shows significant, dose-dependent vasodepressor effect and sinus bradycardia, lasting more than 60 minutes with a maximum at 20 minutes, and shows potent hymodynamic effect^[1].
Methyl maslinate (40 mg/kg) shows antidysrhythmic activity on ischemia-reperfusion dysrhythmia^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar male rats (300-320 g)^[1]
Dosage:

20-60 mg/kg
Administration:

Intraperitoneal injection; once
Result:

Showed significant, dose-response vasodepressor effect and sinus bradicardia.
Antagonized β-Adrenergic.
Showed antidysrhythmic activity.

Chemical Information

CAS No. 22425-82-7
Appearance Solid
Molecular Weight 486.73
Formula C₃₁H₅₀O₄
Color White to off-white
SMILES

O=C([C@](CC[C@]12C)(CCC3(C)C)[C@](C3)([H])C1=CC[C@@]4([H])[C@]2(CC[C@](C(C)([C@H]5O)C)([H])[C@@]4(C[C@H]5O)C)C)OC
Structure Classification
- Terpenoids
- Triterpenes
- Terpenoids
- Pentacyclic Triterpenoids
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Protocols

All Signal Pathway Related

Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Somova LI, et al. Cardiotonic and antidysrhythmic effects of oleanolic and ursolic acids, methyl maslinate and uvaol. Phytomedicine. 2004 Feb;11(2-3):121-9. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote